Patient and Physician Perspectives on Asthma and Its Therapy in Romania: Results of a Multicenter Survey

Dragos Bumbacea 1,2,*†, Carmen Panaitescu 3,4,† and Roxana Silvia Bumbacea 5,6

1 Department of Cardio-Thoracic Medicine, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
2 Department of Pneumology and Acute Respiratory Care, Elias Emergency University Hospital, 011461 Bucharest, Romania
3 Department of Functional Sciences, Physiology, Center of Immuno-Physiology and Biotechnologies (CIFBIOTEH), Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania; cbunu@umft.ro
4 Center for Gene and Cellular Therapies in Treatment of Cancer—OncoGen Center, Pius Brinzeu County Clinical Emergency Hospital, 300723 Timisoara, Romania
5 Department of Allergology, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania; roxana.bumbacea@umfcd.ro
6 Department of Allergology, “Dr. Carol Davila” Nephrology Clinical Hospital, 010731 Bucharest, Romania
* Correspondence: dragos.bumbacea@umfcd.ro; Tel.: +40-21-3161600; Fax: +40-21-2243895
† These authors have equal contribution as co-first authors.

Abstract: Background and Objectives: Patient’s behaviours, attitudes and beliefs related to asthma and its treatment were shown to influence the adherence to therapy and the level of asthma control. This survey aimed to assess the level of asthma control and patient-reported behaviours, attitudes and expectations related to their disease in Romanian patients.

Materials and Methods: This cross-sectional quantitative survey was performed in February-March 2019 and enrolled 70 specialist physicians experienced in asthma management and 433 asthma patients under their care.

Results: Of the 433 patients enrolled, 19.4% had mild asthma, 60.5% moderate asthma and 20.1% severe asthma. For the previous 12 months, asthma symptoms, exacerbations and emergency room visits were common in the sample analysed, with significantly higher figures in severe asthma patients ($p < 0.001$). The most important treatment goal for asthma patients was participation in all activities of daily living, while for physicians this was preventing asthma exacerbations. The valuation of the treatment goals was different between patients with severe asthma and those with mild and moderate forms. Based on the patients’ responses, 3 attitude clusters were identified: empowered savvy (36.5% of the patients), pessimistic non-compliers (43.2%), and anxious strugglers (20.3%). “Empowered savvy” had the lowest frequency of severe asthma, the highest adherence to maintenance therapy and the highest level of confidence in the effectiveness of asthma medication. The opposite of this attitude cluster is the “anxious strugglers”, containing more patients with severe asthma, a higher score for worries about asthma therapy and better self-reported knowledge of their treatment, contrasting with a proportion of 25% taking maintenance therapy only when having breathing difficulties.

Conclusion: Asthma control in Romania remains poor, with frequent exacerbations and hospitalizations. The differences in treatment goals found between patients and physicians and between different asthma severity groups suggest the need for more patient-centred approaches.

Keywords: asthma; asthma therapy; severe asthma; patient behaviour; patient attitudes

1. Introduction

Asthma is one of the most common non-communicable chronic diseases, with an estimated number of 272 million persons affected worldwide in 2017 [1]. In Europe, approximately 30 million persons are living with asthma, and the total annual costs to society due to indirect costs and direct healthcare expenditures predominantly related to
outpatient treatment are estimated to be around 34 billion Eur [2]. As opposed to mild and moderate forms that can be controlled with appropriate treatment, severe asthma is refractory to maximal optimized therapy and to strategies addressing contributory factors, such as inhaler technique and adherence [3]. It affects only 3–10% of patients diagnosed with asthma but has a large impact on patients’ life and is responsible for a large proportion of asthma-associated economic burden [4–6].

Despite the availability of effective asthma therapy, the adherence remains unsatisfactory, with rates ranging between 30% and 70% [7]. Non-adherence to therapy has been associated with poor asthma control and outcomes (including asthma death), increased healthcare resource utilization, and increased indirect costs [8,9]. Causes of non-adherence to asthma therapy are complex and a key factor seems to be related to patient behaviour, itself influenced by patient’s attitudes and beliefs related to the disease and its management [10]. Patient surveys showed that patients overestimate the level of their asthma control [11,12]. Additionally, it has been shown that even patients with persistent asthma do not believe their disease is chronic and tend to only use as-needed medication; hence the adherence increases only when the need for symptom prevention is perceived as high [13–15]. The over-reliance on short-acting beta-agonists (SABA) and underuse of inhaled corticosteroids (ICS) due to patients’ poor understanding of the chronic inflammatory nature of the disease were previously shown as some of the root causes of non-adherence [16]. To reverse this behaviour, the Global Initiative for Asthma (GINA) in its updated guidelines no longer recommends as-needed SABA as the only therapy for mild asthma in adults and adolescents [17].

In Romania, limited data is available on asthma prevalence and control [18,19] and no published data on patients’ attitudes related to asthma and its therapy currently exists. Given the potential to improve asthma control by understanding and addressing patient-related factors, the aim of this survey was to assess the patient-reported behaviours, attitudes and expectations related to asthma and its treatment in Romanian patients. These data would result in a better understanding of patients’ needs, providing useful insights for physicians to optimally tailor their patients’ management.

2. Materials and Methods

2.1. Survey Design and Population

The SABA Trends IN Over-reliance (SABATINO) was a cross-sectional quantitative questionnaire-based survey conducted from 1st of February 2019 to 13th of March 2019. The participants were specialist physicians involved in asthma patients’ management and patients under their care. The sample of physicians consisted of pulmonologists and allergists randomly selected from the national database. Physicians were recruited using computer-assisted telephone interviews (CATI) methodology. The eligible physicians which were interested in participating received an online invitation to the survey with a questionnaire to complete from patients’ medical charts. The following inclusion criteria applied for physicians: between 3 and 35 years since obtaining the specialist physician degree, treating at least an average number of 20 asthma patients per month and currently monitoring at least 5 asthma patients with any type of treatment except maintenance and reliever therapy (MART) in 1 inhaler regimen. Physicians unable to fill out the survey based on patients’ medical charts were excluded. To ensure national representativity, we aimed to enroll 30% of physicians from the capital of the country and the remaining from other geographical regions of Romania. The physicians which participated were asked to enroll at least 5 adult asthma patients under their current care, randomly selected over 2 weeks period, but no more than 1 patient per day. At the time of their visit to the doctor’s office, the patients selected by their treating physician to participate in SABATINO were invited to complete a paper questionnaire specifically designed for this survey. Inclusion criteria for patients were: aged 18 years or older, men or women, with physician-diagnosed asthma irrespective of their disease duration and receiving any type of maintenance treatment except the MART regimen. Eligible patients should have been prescribed SABA therapy at
least once or have been previously informed about reliever therapy, irrespective if at the time of the survey they were using SABA.

As this was a market research survey, no ethics committee approval was required as per local regulations. Data collection was compliant with General Data Protection Regulation (GDPR). No information allowing patient identification was collected. The information allowing physicians’ identification was not transferred from the company performing the data collection to the sponsor of this survey. All of the patients and physicians were informed about data collection and their rights related to GDPR and provided written informed consent before data collection.

2.2. Data Collection

The SABATINO survey was developed by the market research organization ISRA Center (Bucharest, Romania). Questionnaires for physicians were used to collect data on medical specialty, experience (years of practice, average number of patients with asthma seen in a month) and asthma treatment goals. Patients’ data collected by physicians from medical charts were anonymized and included the following variables: disease severity at the time of diagnosis and of the present survey, presence and type of allergies, number of exacerbations and hospitalizations during the past 12 months and current treatment for asthma.

Patients’ questionnaire included 29 items grouped in the following main sections: socio-demographics, asthma diagnosis and manifestations, current asthma treatment, habits connected to and expectations from their asthma treatment, current status of the disease, including asthma-related healthcare use in the past 12 months and impact of the disease on their activities in the last month and year before survey enrollment, patients’ attitude towards asthma and sources of information about asthma. An English version of questionnaires for physicians and patients are included in the Supplementary Table S1.

2.3. Statistical Analysis

Responses were analysed separately for patients and physicians in the overall populations and stratified by the severity of asthma of the patients and the specialty of the physicians. Patients with severe and very severe asthma were analysed together as one group (severe asthma). Descriptive analysis of the responses was provided using mean ± standard deviation (SD) and frequency. The differences in patients’ responses between asthma severity groups were evaluated using analysis of variance (ANOVA) and chi-square methods and a p-value of less than 0.05 was considered significant.

To define patient typologies (clusters of attitudes) a combination of k-means and hierarchical clustering in Convergent Cluster & Ensemble Analysis System (Sawtooth Software, Provo, UT, USA) was used. The first step was to identify the efficient options from a statistical/mathematical point of view using homogeneity (respondents from each attitude cluster to be relatively similar between them on the investigated dimensions), heterogeneity (significant differences between attitude clusters, even if common pillars can exist) and segment dimension relatively balanced (for example not having 80% of the sample in one attitude cluster). Following this, the options/solutions were logically analysed to check their plausibility in the market context. Solutions with attitude clusters that had large overlaps, no coherent profile (no statements matching them) and too large groups to be compared with the others were removed.

3. Results

3.1. Socio-Demographic Characteristics

Of the 430 physicians contacted, 394 gave a positive response via phone and received further information via email. Of these, 70 fulfilled the inclusion criteria, had no exclusion criteria, and accepted to participate (15 allergists and 55 pulmonologists) and were enrolled in this survey. They had a balanced distribution of number of years of experience, geographic location and average number of asthma patients seen per month. Study
physicians enrolled 433 asthma patients. Patients were mostly women, with a mean age of 49.8 years (range 18–89 years), mostly employed or retired, and with a balanced distribution of education history (Table 1).

Table 1. Respondents’ demographic and clinical characteristics.

| Patients Characteristics | N = 433 |
|--------------------------|---------|
| Women, n (%)             | 247 (57.0%) |
| Age, n (%)               |         |
| >55 years                | 160 (37.0%) |
| 40–55 years              | 164 (37.9%) |
| <40 years                | 109 (25.2%) |
| Smokers, n (%)           | 102 (23.6%) |
| Education, n (%)         |         |
| University education     | 154 (35.6%) |
| High school              | 214 (49.4%) |
| Primary or secondary school | 63 (14.5%) |
| Occupational status, n (%) |       |
| Employed                 | 261 (60.3%) |
| Retired                  | 129 (29.8%) |
| Unemployed               | 21 (4.8%) |
| Pupil/student            | 13 (3.0%) |
| Housewife                | 8 (1.8%) |
| Paid leave/maternity leave | 1 (0.2%) |
| Physicians characteristics |         |
| N = 70                   |         |
| Specialty, n (%)         |         |
| Pulmonology              | 55 (78.6%) |
| Allergology              | 15 (21.4%) |
| Years of experience, n (%) |       |
| <15 years                | 29 (41.4%) |
| 15–20 years              | 22 (31.4%) |
| >20 years                | 19 (27.1%) |
| Region of Romania, n (%) |         |
| Bucharest                | 25 (35.7%) |
| East                     | 14 (20.0%) |
| West                     | 9 (12.8%) |
| South                    | 12 (17.1%) |
| Center                   | 10 (14.3%) |
| Average number of asthma patients/month, n (%) | |
| >50 patients             | 24 (34.3%) |
| 30–50 patients           | 28 (40.0%) |
| <30 patients             | 18 (25.7%) |

n/N (%), number (percentage) of patients.

3.2. Clinical Characteristics and Indicators of Asthma Symptoms Control

Of the 433 enrolled patients, 19.4% were classified as mild asthma, 60.5% as moderate asthma and 20.1% as severe asthma. The mean duration of asthma was 8.5 years, with a steady increase from mild to moderate and severe forms (p = 0.002). Physicians reported on average 1.8 asthma exacerbations and 1.0 hospitalizations for asthma per patient in the previous year. The average yearly number of exacerbations and hospitalizations due to asthma was higher in the more severe asthma patients (p < 0.001). The same trend was noticed in patient-reported outcomes. A higher percentage of severe asthma patients reported emergency room visits for asthma and overnight hospital stays during the last year (p < 0.001). Moreover, the number of days off-work or inability to perform usual activities
during the past year was higher in severe asthma patients compared with mild-to-moderate ones \( (p < 0.001; \text{Table 2}) \).

**Table 2.** Clinical characteristics of patients and indicators of asthma symptoms and exacerbations according to asthma severity.

| Physician Reported Characteristics | Mild \( N = 84 \) | Moderate \( N = 262 \) | Severe \( N = 87 \) | Total \( N = 433 \) | \( p \)-Value for Difference between Groups |
|-----------------------------------|------------------|-----------------------|------------------|-------------------|------------------------------------------|
| Years since asthma diagnosis, mean ± SD | 6.9 ± 6.0 | 8.1 ± 7.8 | 10.9 ± 9.2 | 8.5 ± 7.9 | 0.002 |
| Number of exacerbations during the past 12 months, mean ± SD | 1.0 ± 1.0 | 1.5 ± 1.3 | 3.2 ± 1.9 | 1.8 ± 1.5 | <0.001 |

| Distribution of number of exacerbations during the past 12 months, \( n \) (%) |
|------------------------------------------|------------------|-----------------------|------------------|-------------------|
| No exacerbation | 28 (33.3%) | 50 (19.1%) | 2 (2.3%) | 80 (18.5%) | <0.001 |
| 1 exacerbation | 34 (40.5%) | 85 (32.4%) | 12 (14.0%) | 131 (30.3%) |
| 2 exacerbations | 11 (13.1%) | 79 (30.2%) | 16 (18.0%) | 106 (24.5%) |
| ≥3 exacerbations | 6 (7.1%) | 42 (16.0%) | 56 (64.0%) | 104 (24.0%) |

| Number of hospitalizations during the past 12 months, mean ± SD | 0.6 ± 1.5 | 0.8 ± 1.2 | 2.0 ± 1.8 | 1.0 ± 1.5 | <0.001 |

| Distribution of number of hospitalizations in the past 12 months, \( n \) (%) |
|------------------------------------------|------------------|-----------------------|------------------|-------------------|
| No hospitalization | 51 (60.7%) | 127 (48.5%) | 14 (16.1%) | 192 (44.3%) | <0.001 |
| 1 hospitalization | 17 (20.2%) | 70 (26.7%) | 23 (26.4%) | 110 (25.4%) |
| ≥2 hospitalizations | 4 (4.8%) | 42 (16.0%) | 26 (29.9%) | 72 (16.6%) |
| ≥3 hospitalizations | 5 (6.0%) | 13 (5.0%) | 23 (26.4%) | 41 (9.5%) |

| Patients reported characteristics |
|-----------------------------------|------------------|-----------------------|------------------|-------------------|
| Patients with ER visits during the past 12 months, \( n \) (%) | 17 (20.2%) | 66 (25.2%) | 57 (65.5%) | 140 (32.3%) | <0.001 |
| Patients with overnight hospital stay during the past 12 months, \( n \) (%) | 26 (31.0%) | 104 (39.7%) | 62 (71.3%) | 192 (44.3%) | <0.001 |

| No of days with inability to work or carry out usual activities during the past 12 months, \( n \) (%) |
|------------------------------------------|------------------|-----------------------|------------------|-------------------|
| 0–2 days | 42 (50.0%) | 114 (43.5%) | 9 (10.3%) | 165 (38.1%) | <0.001 |
| 3–5 days | 17 (20.2%) | 53 (20.2%) | 15 (17.2%) | 85 (19.6%) |
| 6–9 days | 8 (9.5%) | 17 (6.5%) | 6 (6.9%) | 31 (7.2%) |
| ≥10 days | 3 (3.6%) | 14 (5.3%) | 27 (31.0%) | 44 (10.2%) |
| Do not remember | 14 (16.7%) | 64 (24.4%) | 30 (34.5%) | 108 (24.9%) |

| Asthma impact on patient’s activities during last month, \( n \) (%) |
|------------------------------------------|------------------|-----------------------|------------------|-------------------|
| High & Very high | 3 (3.6%) | 17 (6.5%) | 15 (17.2%) | 35 (8.1%) |
| Moderate | 10 (11.9%) | 68 (26.0%) | 29 (33.3%) | 107 (24.7%) | <0.001 |
| Limited | 24 (28.6%) | 83 (31.7%) | 32 (36.8%) | 139 (32.1%) |
| Very limited | 21 (25.0%) | 60 (22.9%) | 10 (11.5%) | 91 (21.0%) |
| None | 26 (31.0%) | 34 (13.0%) | 1 (1.1%) | 61 (14.1%) |

ER, emergency room; \( n/N \) (%), number (percentage) of patients; SD, standard deviation.

### 3.3. Asthma Therapy

Overall, based on medical charts, 94.0% of patients participating in SABATINO survey had maintenance therapy with a separate reliever therapy prescribed at the time of the survey, and 6.0% had reliever therapy only. Severe asthma patients were prescribed more reliever and maintenance medication than mild-to-moderate ones, mostly biological therapy, oral steroids, anticholinergic and antileukotrienes (Table 3).
Table 3. Asthma therapy usage as reported by patients and physicians.

|                  | Mild N = 84 | Moderate N = 262 | Severe N = 87 | Total N = 433 | p-Value for Difference between Groups |
|------------------|-------------|------------------|---------------|---------------|--------------------------------------|
| Maintenance therapy type, n (%) |             |                  |               |               |                                      |
| ICS/LABA # | 48 (57.1%) | 200 (76.3%) | 72 (82.8%) | 320 (73.9%) |                                      |
| ICS           | 23 (27.4%) | 28 (10.7%) | 20 (23.0%) | 71 (16.4%)   |                                      |
| Antileukotrienes | 14 (16.7%) | 66 (25.2%) | 39 (44.8%) | 119 (27.5%) |                                      |
| Anticholinergic | 3 (3.6%)  | 10 (3.8%)  | 20 (23.0%) | 33 (7.6%)    |                                      |
| Xanthines      | 2 (2.4%)  | 10 (3.8%)  | 4 (4.6%)   | 16 (3.7%)    |                                      |
| OCS            | 1 (1.2%)  | 15 (5.7%)  | 24 (27.6%) | 40 (9.2%)    |                                      |
| Biological therapy | 0 (0.0%) | 2 (0.8%)   | 8 (9.2%)   | 10 (2.3%)    |                                      |

| Reliever therapy (SABA), n (%) | 60 (71.4%) | 215 (82.1%) | 80 (92.0%) | 355 (82.0%) |                                      |

Physician Reported Characteristics

Patients reported characteristics

| Mean number of reliever inhalers purchased in the previous 12 months, mean ± SD | 3.1 ± 2.6 | 3.1 ± 2.2 | 5.1 ± 3.4 | 3.6 ± 2.8 | <0.001 |
| Mean number of maintenance inhalers purchased in the previous 12 months, mean ± SD | 8.0 ± 4.2 | 8.4 ± 4.0 | 7.7 ± 4.3 | 8.2 ± 4.1 | 0.51   |

Usage of reliever inhalers during last month, n (%)

| Never | 46 (54.8%) | 86 (32.8%) | 17 (19.5%) | 149 (34.4%) | <0.001 |
| Some weeks | 26 (31.0%) | 148 (56.5%) | 31 (35.6%) | 205 (47.3%) |                                      |
| Every week | 12 (14.3%) | 28 (10.7%)  | 39 (44.8%) | 79 (18.2%)  |                                      |

Over-the-counter reliever therapy, n (%) | 28 (33.3%) | 79 (30.2%) | 42 (48.3%) | 149 (34.4%) | 0.008 |

# Only as combination therapy. GP, general practitioner; ICS, inhaled corticosteroids; LABA, long-acting beta agonists; n/N (%), number (percentage) of patients; OCS, oral corticosteroids; SABA, short-acting beta agonists; SD, standard deviation

Based on the patients’ completed questionnaires, 86.1% of patients reported regular administration of their asthma medication. Reliever medication was used by 79.7% of patients for symptom relief only and 19.2% also used it to prevent asthma symptoms. Maintenance medication was used daily to prevent asthma symptoms by 81.3% of those using this type of medication, with 17.9% of the patients reporting the use of their maintenance medication only when experiencing asthma symptoms. Per severity groups, the use of maintenance therapy only when having asthma symptoms was reported by 10 patients (12.2%) with mild asthma, 45 patients (18.1%) with moderate asthma and 18 patients (23.4%) with severe asthma (p = 0.390).

3.4. Valuation of Treatment Goals

The most important treatment goals frequently identified by patients were: participation in all activities of daily living, prevention of asthma exacerbations and prevention of chronic symptoms that interfere with daily living. The most important treatment goals most frequently identified by physicians were preventing asthma exacerbations, allowing the person to participate in all activities of daily living and preventing asthma mortality. Valuation was different between pulmonologists and allergists and between patients with severe asthma and those with mild and moderate forms (Figure 1).

3.5. Patients Attitudes toward Asthma

The patients in the survey had similar attitudes on the effectiveness of the therapy and the ease of use of any medication irrespective of their asthma severity. However, patients with severe asthma had greater concerns about their therapy and the burden of asthma medication; thus, they scored higher in questions related to worries on having breathing difficulties, the use of medication when feeling well and self-adjustment of medication (Supplementary Table S2).
prevention of chronic symptoms that interfere with daily living. The most important treatment goals most frequently identified by physicians were preventing asthma exacerbations, allowing the person to participate in all activities of daily living and preventing asthma mortality. Valuation was different between pulmonologists and allergists and between patients with severe asthma and those with mild and moderate forms (Figure 1).

**Figure 1.** Valuation of treatment goals in physicians according to their specialty (a), in patients according to asthma severity (b) and in physicians as compared to patients (c). “Reduction in asthma mortality” was not a treatment goal in patient questionnaire due to cultural reasons.

3.5. Patients Attitudes toward Asthma

The patients in the survey had similar attitudes on the effectiveness of the therapy and the ease of use of any medication irrespective of their asthma severity. However, patients with severe asthma had greater concerns about their therapy and the burden of asthma medication; thus, they scored higher in questions related to worries on having breathing difficulties, the use of medication when feeling well and self-adjustment of medication (Supplementary Table S2).

Three attitude clusters were identified based on patients’ responses to questions on attitudes towards asthma and its therapy (Supplementary Table S3): empowered savvy (36.5% of the patients), pessimistic non-compliers (43.2% of patients), and anxious strugglers (20.3% of the patients).

“Empowered savvy” patients were aware and knowledgeable of their condition and felt in control even when the worsening of their symptoms occur. Compared to the other clusters, the patients in this cluster generally had a higher level of education, were less likely to be smokers and had the lowest mean number of exacerbations and hospitalizations during the previous 12 months. Furthermore, they more frequently reported administering their asthma medication, the use of reliever therapy when coughing or having breathing difficulties and daily use of maintenance therapy to prevent asthma symptoms (Table 4).

The patients in the “pessimistic non-compliers” cluster had a limited understanding of asthma therapies and as a result, they considered the therapy a burden, leading to complaints about price and multiple inhaler usage, and embarrassment related to inhaler usage in public. Lacking the knowledge or understanding about the ways to prevent a worsening of symptoms, these patients felt scared and worried, unable to manage by themselves such situations. Compared to the other clusters, patients in this attitude cluster were older, had a lower level of higher education and reported the lowest frequency of administering their asthma medication (Table 4).
Table 4. Patient characteristics for each attitude cluster identified.

|                                | Empowered Savvy      | Pessimistic Non-Compliers | Anxious Strugglers | p-Value for Difference between Groups |
|--------------------------------|----------------------|---------------------------|--------------------|--------------------------------------|
|                                | N = 158              | N = 187                   | N = 88             |                                      |
| **Age, years**                 | 49.0 ± 13.4          | 52.0 ± 13.9               | 46.0 ± 15.7        | 0.002                                |
| Smokers, n (%)                 | 28 (17.7%)           | 39 (20.9%)                | 35 (39.8%)         | <0.001                               |
| **Education, n (%)**           |                      |                           |                    |                                      |
| University education           | 75 (47.5%)           | 49 (26.2%)                | 30 (34.1%)         | 0.003                                |
| Highschool                     | 62 (39.2%)           | 110 (58.8%)               | 42 (47.7%)         |                                      |
| Primary or secondary school    | 21 (13.3%)           | 27 (14.4%)                | 15 (17.0%)         |                                      |
| **Asthma severity, n (%)**     |                      |                           |                    |                                      |
| Mild                           | 42 (26.6%)           | 28 (15.0%)                | 14 (15.9%)         | 0.003                                |
| Moderate                       | 94 (59.5%)           | 121 (64.7%)               | 47 (53.4%)         |                                      |
| Severe                         | 22 (13.9%)           | 38 (20.3%)                | 27 (30.7%)         |                                      |
| **Number of exacerbations**    |                      |                           |                    |                                      |
| during the past 12 months, mean ± SD | 1.5 ± 1.7        | 1.7 ± 1.4                 | 2.4 ± 1.4          | <0.001                               |
| Number of hospitalizations     |                      |                           |                    |                                      |
| during the past 12 months, mean ± SD | 0.6 ± 1.7        | 1.1 ± 1.1                 | 1.7 ± 1.4          | <0.001                               |
| **Maintenance therapy type,**  |                      |                           |                    |                                      |
| n (%)                          |                      |                           |                    |                                      |
| ICS/LABA *                     | 132 (83.5%)          | 127 (67.9%)               | 61 (69.3%)         |                                      |
| Antihistamines                 | 24 (15.2%)           | 61 (32.6%)                | 42 (47.7%)         |                                      |
| Antileukotrienes               | 44 (27.8%)           | 51 (27.3%)                | 24 (27.3%)         |                                      |
| ICS                            | 14 (8.9%)            | 23 (12.3%)                | 34 (38.6%)         |                                      |
| OCS                            | 12 (7.6%)            | 11 (5.9%)                 | 17 (19.3%)         |                                      |
| **Reliever therapy (SABA), n (%)** | 123 (77.8%)      | 165 (88.2%)               | 67 (76.1%)         | <0.05                                |
| Usage of asthma therapy, n (%) |                      |                           |                    |                                      |
| Always                         | 146 (92.4%)          | 147 (78.6%)               | 80 (90.9%)         | <0.001                               |
| Sometimes                      | 12 (7.6%)            | 40 (21.4%)                | 8 (9.1%)           |                                      |
| **Reliever therapy use, n (%)** |                      |                           |                    |                                      |
| When coughing or having        | 139 (88.0%)          | 145 (77.5%)               | 61 (69.3%)         | 0.002                                |
| breathing difficulties         |                      |                           |                    |                                      |
| Sometimes to prevent asthma    | 18 (11.4%)           | 38 (20.3%)                | 27 (30.7%)         |                                      |
| exacerbations                  |                      |                           |                    |                                      |
| Usage of reliever inhalers     | 91 (57.6%)           | 125 (66.8%)               | 68 (77.3%)         | 0.007                                |
| during last month, n (%)       |                      |                           |                    |                                      |
| Mean number of reliever        | 3.4 ± 2.5            | 3.6 ± 2.9                 | 3.9 ± 2.8          | 0.448                                |
| inhalers purchased in the      |                      |                           |                    |                                      |
| previous 12 months, mean ± SD  |                      |                           |                    |                                      |
| **Maintenance therapy use,**   |                      |                           |                    |                                      |
| n (%)                          |                      |                           |                    |                                      |
| Every day                      | 140 (88.6%)          | 140 (74.9%)               | 51 (58.0%)         | 0.001                                |
| When coughing or having        | 15 (9.5%)            | 36 (19.3%)                | 22 (25.0%)         |                                      |
| breathing difficulties         |                      |                           |                    |                                      |
| Mean number of maintenance     | 10.1 ± 3.3           | 7.3 ± 4.0                 | 5.5 ± 4.0          | <0.001                               |
| inhalers purchased in the      |                      |                           |                    |                                      |
| previous 12 months, mean ± SD  |                      |                           |                    |                                      |

* Only as combination therapy. ICS, inhaled corticosteroids; LABA, long-acting beta agonists; n/N (%), number (percentage) of patients; OCS, oral corticosteroids; SABA, short-acting beta agonists; SD, standard deviation.
The patients in the “anxious strugglers” cluster reported a good knowledge of asthma therapies and management of symptoms but exhibited worries regarding the efficiency and potential side effects of their medication. They were worried about taking too much medication when feeling well, and therefore they preferred to adjust the doses. The patients in this attitude cluster were more likely to be smokers, with severe asthma and had more exacerbations and hospitalizations during the previous 12 months. They also more frequently reported the use of reliever medication to prevent asthma symptoms and of maintenance therapy only when coughing and having breathing difficulties and less frequently daily (Table 4).

4. Discussion

SABATINO is the first survey conducted in Romania specifically investigating the adult patients’ expectations and attitudes towards asthma and its treatment. It shows that despite advances in asthma therapy, significant unmet needs persist in terms of asthma care, particularly in those with severe disease and points towards a lack of improvement in asthma control.

Asthma symptoms and exacerbations were common in the sample analysed; for almost half of the patients, physicians reported ≥2 exacerbations and for a fraction of them ≥2 hospitalizations within 12 months prior to the survey. Moreover, one-third of the patients reported ER visits. The situation was more dramatic when data were analysed according to the asthma severity, with severe asthma patients having more exacerbations and hospitalizations than mild-to-moderate ones. Unsurprisingly, severe asthma patients used significantly more reliever medication (including over-the-counter use) than mild-to-moderate patients. These results align with previously published results of surveys performed in patients with asthma, which also showed a persistence of significant exacerbations and low levels of symptom control in other European populations [11,12]. It is known that patients with severe asthma are a category characterized by a high burden of illness due to poor symptom control, experiencing frequent and often life-threatening exacerbations, associated comorbidities, and low quality of life [20–22]. A recent study evaluated the experiences and impact of severe asthma on patient’s life and showed significant emotional distress in these patients because of the disease and its therapy [21]. This study identified the neglected needs of patients with severe asthma, such as “empathy and understanding” and “encouragement” [21]. It also pointed towards the need for a support service that would improve adherence problems resulting in concerns about medication side effects [21].

The behaviour of SABATINO participants who reported the use of reliever therapy only to prevent exacerbation or of maintenance therapy when experiencing symptoms is not uncommon [13–15]. Previous reports suggested that low adherence to the prescribed therapy probably reflects patients’ beliefs about medication and their personality traits [13,23,24]. In our survey, we identified 3 attitude clusters corresponding to different personality traits with distinct clinical characteristics. “Empowered savvy” had the lowest frequency of severe asthma, the highest adherence to maintenance therapy and the highest level of confidence in the effectiveness of asthma medication. The opposite of this attitude cluster is the “anxious strugglers” with more patients with severe asthma, a higher score for worries about asthma therapy (side effects, dose, and appropriateness especially when symptoms were absent) and better knowledge of their treatment as self-reported which was in contradiction with their behaviour, with 25% of them reporting taking maintenance therapy only when having breathing difficulties. The clusters identified in SABATINO show similarities to clusters previously identified in other populations, which reported well-controlled asthma among patients with few concerns about their medications [25,26]. The non-confidence in the effectiveness of asthma medication and negative concerns about therapy were associated with reduced adherence to therapy [16] and uncontrolled disease [26]. These findings suggest that asthma management should not only be tailored for the severity of the disease but
should also consider patients’ beliefs and behaviours, specifically targeting medication concerns with the aim to improve treatment adherence [24,27].

The lack of adherence to prescribed therapy and empowerment in asthma self-management may also reflect the discrepancy between treatment goals as seen by patients and physicians and between different asthma severity groups, suggesting different patients’ needs. For example, the most important treatment goal reported by the highest percentage of physicians was preventing asthma exacerbations, while for patients it was the participation in activities of daily living. The difference in asthma expectations between patients and physicians when it comes to asthma control is not new, and points toward unmet patient needs [28–30]. Previous studies showed that physicians tend to focus on asthma control while patients are more concerned about long-term health and costs [28–30]. When analysed by the severity of the disease, in our survey, the most important goals identified by the highest percentage of patients was participation in daily-life activities for those with mild and moderate asthma and preventing chronic symptoms that interfere with daily lives in those with severe asthma. These results indicate a different valuation of treatment goals that vary according to the severity of the disease and the need for targeted approaches. The one-size-fit-all approach may not be suitable, and physicians should work with their respiratory patients to define individualized treatment goals through a shared-decision making process.

This survey has several limitations that may limit the generalization of our findings. This was a cross-sectional survey, and the selection bias cannot be precluded. Moreover, the sample size, especially of those with severe asthma was limited. It was not designed to compare patients with different asthma severity, but it would be of interest to observe these differences in future surveys designed for this purpose.

5. Conclusions

The results of this survey point to suboptimal asthma control in Romania and underlines the significant burden of asthma, and especially of severe asthma, in Romania, with implications for clinical practice and policymakers. The different valuations of the treatment goals observed in patients and physicians, and in different asthma severity groups suggest the need for individualized approaches, more patient-centred. Guidelines recommendations should be adapted, with practical tools more adequate for the Romanian healthcare setting to be provided for the routine use of clinicians, including patient educational programs. The ultimate common goal should be to improve patients’ knowledge and self-awareness through a solid therapeutic alliance with the treating physicians, thus enabling optimal symptom control.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/medicina57101089/s1, Supplementary Table S1. Questionnaires used for physicians and patients in the SABATINO survey, Supplementary Table S2. Patients’ attitudes toward asthma by severity of asthma, Supplementary Table S3. Patients’ attitude toward asthma according to attitude clusters identified

Author Contributions: Conceptualization, D.B., C.P. and R.S.B.; methodology, D.B., C.P. and R.S.B.; formal analysis, D.B., C.P. and R.S.B.; writing—original draft preparation, D.B.; writing—review and editing, D.B., C.P. and R.S.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by AstraZeneca Romania. The sponsor participated in the survey design and facilitated the overall operational process, including data collection and statistical analyses. The sponsor was also involved in the decision to publish this manuscript.

Institutional Review Board Statement: Ethical review and approval were waived for this study, due to the fact it was a market research survey. Data collection was compliant with GDPR. No information allowing patient identification was collected. The information allowing physicians’ identification was not transferred from the company performing the data collection to the sponsor of this survey.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Data Availability Statement: Research data are not shared.

Acknowledgments: Operational support and statistical analysis were provided by ISRA Center (Bucharest, Romania) and medical writing support by MedInteractiv (Bucharest, Romania) on behalf of AstraZeneca Romania.

Conflicts of Interest: D Bumbacea reports personal fees from AstraZeneca, personal fees from Chiesi, personal fees from Novartis, and grants and personal fees from Sanofi, outside the submitted work; RS Bumbacea reports personal fees from AstraZeneca, personal fees from Chiesi, personal fees from Ewopharma, personal fees from Novartis, outside the submitted work; C Panaitescu has nothing to disclose.

References

1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018, 392, 1789–1858.

2. European Respiratory Society. European Lung White Book. 2013. Available online: https://www.erswhitebook.org (accessed on 27 February 2020).

3. Global Initiative for Asthma. Difficult to Treat & Severe Asthma in Adolescents and Adult Patients. Diagnosis and Management. 2019. Available online: https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v20-wms-1pdf (accessed on 19 February 2020).

4. McDonald, V.M.; Maltby, S.; Reddel, H.K.; King, G.G.; Wark, P.A.; Smith, L.; Upham, J.W.; James, A.L.; Marks, G.B.; Gibson, P.G. Severe asthma: Current management and future directions-A roundtable report. Respir Res 2017, 22, 53–60. [CrossRef] [PubMed]

5. Dean, B.B.; Calimlim, B.C.; Sacco, P.; Aguilar, D.; Maykut, R.; Tinkelman, D. Uncontrolled asthma: Assessing quality of life and productivity of children and their caregivers using a cross-sectional Internet-based survey. Health Qual. Life Outcomes 2010, 8, 96. [CrossRef] [PubMed]

6. Hekking, P.P.; Wener, R.R.; Amelink, M.; Zwinderman, A.H.; Bouvy, M.L.; Bel, E.H. The prevalence of severe refractory asthma. J Allergy Clin. Immunol. 2015, 135, 896–902. [CrossRef] [PubMed]

7. Bender, B.; Milgrom, H.; Rand, C. Nonadherence in asthmatic patients: Is there a solution to the problem? Ann. Allergy Asthma Immunol. 1997, 79, 177–185. [CrossRef]

8. Bender, B.G.; Rand, C. Medication non-adherence and asthma treatment cost. Curr. Opin. Allergy Clin. Immunol. 2004, 4, 191–195. [CrossRef]

9. Royal College of Physicians. Why Asthma Still Kills: The National Review of Asthma Deaths (NRAD); Confidential Enquiry Report 2014. London: Royal College of Physicians. 2014. Available online: https://www.rcplondon.ac.uk/file/868/download (accessed on 11 June 2020).

10. George, M.; Bender, B. New insights to improve treatment adherence in asthma and COPD. Patient Prefer. Adherence 2019, 13, 1325–1334. [CrossRef]

11. Sastre, J.; Fabbi, L.M.; Price, D.; Wahn, H.U.; Bousquet, J.; Fish, J.E.; Murphy, K.; Sears, M.R. Insights, attitudes, and perceptions about asthma and its treatment: A multinational survey of patients from Europe and Canada. World Allergy Organ. J. 2016, 9, 13. [CrossRef]

12. Price, D.; Fletcher, M.; van der Molen, T. Asthma control and management in 8000 European patients: The REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim. Care Respir. Med. 2014, 24, 14009. [CrossRef]

13. Kaptein, A.A.; Hughes, B.M.; Scharloo, M.; Fischer, M.J.; Snoei, L.; Weinman, J.; Rabe, K.F. Illness perceptions about asthma are determinants of outcome. J Asthma 2008, 45, 459–464. [CrossRef]

14. Halm, E.A.; Mora, P.; Leventhal, H. No symptoms, no asthma: The acute episodic disease belief is associated with poor self-management among inner-city adults with persistent asthma. Chest 2006, 129, 573–580. [CrossRef] [PubMed]

15. Bidad, N.; Barnes, N.; Griffiths, C.; Horne, R. Understanding patients’ perceptions of asthma control: A qualitative study. Eur. Respir. J. 2018, 51, 1701346. [CrossRef] [PubMed]

16. O’Byrne, P.M.; Jenkins, C.; Bateman, E.D. The paradoxes of asthma management: Time for a new approach? Eur. Respir. J. 2017, 50, 1701103. [CrossRef]

17. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2019. Available online: www.ginasthma.org (accessed on 29 February 2020).

18. Bumbacea, D.; Ionita, D.; Ciocanu, M.; Tudose, C.; Bogdan, M. Prevalence of asthma symptoms, diagnosis and treatment use in Romania. Eur. Respir. J. 2013, 42, 964. [PubMed]

19. Chereches-Panta, P.; Sorin, C.; Dumitrescu, D.; Marshall, M.; Mirestean, I.; Muresan, M.; Iacob, D.; Farcau, M.; Ichim, G.E.; Nanulescu, M.V. Epidemiological survey 6 years apart: Increased prevalence of asthma and other allergic diseases in schoolchildren aged 13–14 years in Cluj-Napoca, Romania (based on isaac questionnaire). Maedica 2011, 6, 10–16. [PubMed]
20. Chung, K.F.; Wenzel, S.E.; Brozek, J.L.; Bush, A.; Castro, M.; Sterk, P.J.; Adcock, I.M.; Bateman, E.D.; Bel, E.H.; Bleecker, E.R.; et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur. Respir. J.* 2014, 43, 343–373. [CrossRef] [PubMed]

21. Foster, J.M.; McDonald, V.M.; Guo, M.; Reddel, H.K. “I have lost in every facet of my life”: The hidden burden of severe asthma. *Eur. Respir. J.* 2017, 50, 1700765. [CrossRef]

22. McDonald, V.M.; Hiles, S.A.; Jones, K.A.; Clark, V.L.; Yorke, J. Health-related quality of life burden in severe asthma. *Med. J. Aust.* 2018, 209(Suppl. 2), S28–S33. [CrossRef]

23. Menckeberg, T.T.; Bouvy, M.L.; Bracke, M.; Kapteijn, A.A.; Leufkens, H.G.; Raaijmakers, J.A.; Horne, R. Beliefs about medicines predict refill adherence to inhaled corticosteroids. *J. Psychosom. Res.* 2008, 64, 47–54. [CrossRef]

24. van der Molen, T.; Fletcher, M.; Price, D. Identifying Patient Attitudinal Clusters Associated with Asthma Control: The European REALISE Survey. *J. Allergy Clin. Immunol. Pract.* 2018, 6, 962–971. [CrossRef]

25. Unni, E.; Shiyanbola, O.O. Clustering medication adherence behavior based on beliefs in medicines and illness perceptions in patients taking asthma maintenance medications. *Curr. Med. Res. Opin.* 2016, 32, 113–121. [CrossRef] [PubMed]

26. Axelsson, M.; Cliffordson, C.; Lundback, B.; Lotvall, J. The function of medication beliefs as mediators between personality traits and adherence behavior in people with asthma. *Patient Prefer. Adherence* 2013, 7, 1101–1109. [CrossRef] [PubMed]

27. Braido, F.; Chrystyn, H.; Baiardini, I.; Bosnic-Anticevich, S.; van der Molen, T.; Dandurand, R.J.; Chisholm, A.; Carter, V.; Price, D.; Group, R.E. “Trying, But Failing”—The role of inhaler technique and mode of delivery in respiratory medication adherence. *J. Allergy Clin. Immunol. Pract.* 2016, 4, 823–832. [CrossRef] [PubMed]

28. Hyland, M.E.; Stahl, E. Asthma treatment needs: A comparison of patients’ and health care professionals’ perceptions. *Clin. Ther.* 2004, 26, 2141–2152. [CrossRef]

29. Gelhorn, H.L.; Balantac, Z.; Ambrose, C.S.; Chung, Y.N.; Stone, B. Patient and physician preferences for attributes of biologic medications for severe asthma. *Patient Prefer. Adherence* 2019, 13, 1253–1268. [CrossRef] [PubMed]

30. Williams, B.; Steven, K.; Sullivan, F.M. Tacit and transitional: An exploration of patients’ and primary care health professionals’ goals in relation to asthma. *Soc. Sci. Med.* 2011, 72, 1359–1366. [CrossRef] [PubMed]